Pediatric Alveolar Proteinosis Treatment & Management
- Author: Danielle M Goetz, MD; Chief Editor: Girish D Sharma, MD, FCCP, FAAP more...
The appropriate management depends on the patient's age at presentation, the severity of symptoms, and the anticipated course of the disease. Any predisposing conditions (eg, malignancy, infection) should be treated because resolution of the primary condition may lead to remission of secondary pulmonary alveolar proteinosis (PAP). Reports describe spontaneous remission of primary PAP without medical intervention.[9, 18] Treatment of congenital (genetic) PAP is often difficult. In lysinuric protein intolerance, even after lung transplant, PAP can recur and lead to relapse and death.
- Mechanical ventilation: Mechanical ventilation is necessary in children with congenital PAP. No reports show any benefit from the use of high-frequency oscillatory ventilation (HFOV) or other unconventional forms of mechanical ventilation.
- Gene therapy: Because congenital (genetic) PAP is a single-gene defect, it may be a candidate disease for gene therapy. GM-CSF therapy does not seem to be effective in these cases.
- GM-CSF therapy: Several trials of GM-CSF therapy for autoimmune PAP have shown encouraging results.[32, 33] In a recent meta-analysis of the efficacy of GM-CSF therapy in autoimmune PAP, there were 5 observational studies (94 patients), which showed a response rate of 43-92%, with the pooled response rate being 58.6% (95% confidence interval, 42.7-72.9).
- GM-CSF may be inhaled or subcutaneously administered and may be considered an alternative to whole-lung lavage. However, sargramostim (Bayer) was withdrawn from several national markets and may require specific permission from national health authorities, depending on the country.
- Rituximab (monoclonal antibody against B lymphocyte specific antigen CD20) treatment decreased anti-GM-CSF antibody levels in BAL fluid in 7 of 9 patients. Rituximab appeared to improve alveolar macrophage lipid metabolism (reduction in Oil Red O intensity in alveolar macrophages) and increased total protein and surfactant protein A levels.
The mainstay of therapy in PAP is whole-lung lavage. Patients who undergo lavage during the course of their illness have improved survival rates. In addition, 84% of the published cases reported clinical, physiologic, and radiographic improvements after initial therapeutic lavage.[18, 35] Response rates substantially differ when patients are divided into cohorts by age. Patients younger than 20 years old have a 58% response compared with 90% patients older than 40 years.
The mechanism of improvement is unknown but is presumed to be the removal of surfactant buildup or minimizing the effect of macrophage dysfunction. Successful treatment with lobar lavage with fiberoptic bronchoscopy is also reported.
Other surgical options include extracorporeal membrane oxygenation (ECMO) and lung transplantation.[1, 36]
- Lung lavage
- In brief, the procedure involves single-lung ventilation while the contralateral lung is lavaged with sodium chloride solution. A double-lumen endotracheal tube (ETT) is used in older children to allow for simultaneous ventilation of one lung and lavage of the contralateral lung with the patient under general anesthesia.[37, 38, 39, 40, 41]
- Isotonic sodium chloride solution with or without heparin is generally instilled into the lungs. The patient is ventilated with 100% oxygen, and the dependent lung is filled with 3-5 mL/kg of fluid and drained. Lavage is repeated until no sediment material is obtained.
- The lungs retain variable amounts of fluid. Chest percussion is reported to improve the yield of material. The patient should be intermittently suctioned through the ETT after the procedure to remove any residual fluid.
- Serum electrolyte levels should be monitored because fluid fluxes may cause electrolyte imbalances.
- The use of whole-lung lavage is less well established in young infants and newborns than in others primarily because of the technical difficulties associated with passing a necessarily large ETT through a small glottis. However, the success rate of this procedure is described in infants as small as 5 kg. In smaller infants, whole-lung lavage performed while the infant is receiving cardiopulmonary bypass or ECMO is reported.
- A technique was described using a balloon-wedge pressure catheter into a main bronchus through the endotracheal tube. Complete filling of the lung was indicated by slight proximal movement of the catheter balloon.
- Spock reported the use of a nasotracheal tube and a hyperbaric chamber to prevent hypoxemia.
- ECMO: ECMO may provide a bridge to lung transplantation or definitive lung lavage in patients who are either too critically ill or too small to undergo lavage.
- Lung transplantation
- At this time, the only definitive therapy for CAP is bilateral lung transplantation.
- PAP has recurred in lungs transplanted into adults. It has also recurred in lysinuric protein intolerance in children after lung transplantation.
- Twenty-four cases of spontaneous resolution of secondary PAP were reported, suggesting some surviving patients, with or without therapy, may enter a quiescent state.
See the list below:
- Consult a neonatologist and a pulmonologist when a patient has congenital PAP. An opinion from or a referral to a center with expertise in neonatal lung transplantation is required when this option is being considered.
- Consultation with a geneticist should be offered to parents of a child with congenital PAP. Antenatal screening for this condition is now possible.
- Acquired PAP
- For the older child, consultation with a pulmonologist is mandatory.
- The opinions of an immunologist, an infectious disease specialist, or a hematologist may also be necessary, depending on clinical findings and suspicion for secondary PAP.
No specific diet is necessary. However, as in any chronic disease, attention should be paid to the provision of sufficient calories to maintain adequate growth. Young infants with feeding difficulties due to dyspnea may require feeding through a nasogastric or gastrostomy tube. When prescribing a high-calorie diet, ensure that the carbohydrate load is not excessive because this may exacerbate respiratory difficulties due to a high respiratory quotient and subsequent high CO2 burden.
In general, the patient's degree of dyspnea limits his or her activity. No limitations on activity are necessary.
Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003 Dec 25. 349(26):2527-39. [Medline].
[Guideline] Leth S, Bendstrup E, Vestergaard H and Hilberg O. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology. 2013. 18:82-91.
Patel SM, Sekuguchi H, Reynold J and Krowks M. Pulmonary alveolar proteinosis. Canadian Respiratory Journal. 2012. 19:243-45.
Raj D, Bhutia TD, Mathur S, Kabra SK, Lodha R. Pulmonary Alveolar Proteinosis Secondary to Pneumocystis jiroveci Infection in an Infant with Common Variable Immunodeficiency. Indian J Pediatr. 2013 May 5. [Medline].
Samuels MP, Warner JO. Pulmonary alveolar lipoproteinosis complicating juvenile dermatomyositis. Thorax. 1988 Nov. 43(11):939-40. [Medline].
deMello DE, Nogee LM, Heyman S, et al. Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr. 1994 Jul. 125(1):43-50. [Medline].
Enaud L, Hadchouel A, Coulomb A, Berteloot L, Lacaille F, Boccon-Gibod L, et al. Pulmonary alveolar proteinosis in children on La Réunion Island: a new inherited disorder?. Orphanet J Rare Dis. 2014 Jun 14. 9:85. [Medline].
Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958 Jun 5. 258(23):1123-42. [Medline].
Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest. 1998 Nov. 114(5):1357-62. [Medline].
Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994 Apr. 93(4):1860-3. [Medline].
Borie R, Danel C, Debray MP, Taille C, Dombret MC, Aubier M, et al. Pulmonary alveolar proteinosis. European Respiratory Reviews. 2011. 20:98-107.
Carey B & Trapnell B. Molecular basis of pulmonary alveolar proteinosis. Clinical Immunology. 2010. 135:223-25. [Full Text].
Knight DP, Knight JA. Pulmonary alveolar proteinosis in the newborn. Arch Pathol Lab Med. 1985 Jun. 109(6):529-31. [Medline].
Coleman M, Dehner LP, Sibley RK, Burke BA, L'Heureux PR, Thompson TR. Pulmonary alveolar proteinosis: an uncommon cause of chronic neonatal respiratory distress. Am Rev Respir Dis. 1980 Mar. 121(3):583-6. [Medline]. [Full Text].
Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore). 1994 Mar. 73(2):103-9. [Medline].
Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc. 1987 Jun. 62(6):499-518. [Medline].
Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002 Jul 15. 166(2):215-35. [Medline].
Inoue Y et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. American Journal of Respiratory and Critical Care Medicine. 2008. 177:752-62.
Schumacher RE, Marrogi AJ, Heidelberger KP. Pulmonary alveolar proteinosis in a newborn. Pediatr Pulmonol. 1989. 7(3):178-82. [Medline].
Nogee LM, Dunbar AE 3rd, Wert S, Askin F, Hamvas A, Whitsett JA. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest. 2002 Mar. 121(3 Suppl):20S-21S. [Medline].
Doerschuk CM. Pulmonary Alveolar Proteinosis- Is Host Defense Awry?. N Engl J Med. Feb 2007. 356:547-49.
Khan A, Agarwal R, and Aggarwal A. Effectiveness of granulocyte-macrophage colony-stimulating factor therapy in autoimmune pulmonary alveolar proteinosis. Chest. 2012. 141:1273-83.
Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007 Feb 8. 356(6):567-79. [Medline].
Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics. 1996 Jan. 97(1):117-22. [Medline].
Bonella F, Ohshimo S, Miaotian C, Griese M, Guzman J and Costable U. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases. 2013. 2013:[Full Text].
Mazzone P, Thomassen MJ, Kavuru M. Our new understanding of pulmonary alveolar proteinosis: what an internist needs to know. Cleve Clin J Med. 2001 Dec. 68(12):977-8, 981-2, 984-5 passim. [Medline].
Albafouille V, Sayegh N, De Coudenhove S, et al. CT scan patterns of pulmonary alveolar proteinosis in children. Pediatr Radiol. 1999 Mar. 29(3):147-52. [Medline].
Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest. 1997 Feb. 111(2):460-6. [Medline].
Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001 Feb. 163(2):524-31. [Medline].
Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000 Apr. 161(4 Pt 1):1143-8. [Medline].
Malur A, Kavuru M, Marshall I, Barna B, Huizar I, Karnekar R, et al. Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis. Respiratory Research. 2012. 13:46. [Full Text].
Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr. 1994 Sep. 125(3):356-61. [Medline].
Lingadevaru H, Romano MA, Fauman K, Cooley E, Annich GM, Cornell TT. Challenges during repeat extracorporeal life support in a patient with pulmonary alveolar proteinosis. ASAIO J. 2011 Sep-Oct. 57(5):473-4. [Medline].
Claypool WD, Rogers RM, Matuschak GM. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest. 1984 Apr. 85(4):550-8. [Medline].
DiFusco LA, Verma RK. Whole-lung lavage for pediatric patients with pulmonary alveolar proteinosis. AORN J. 2013 Jul. 98(1):50-67; quiz 68-70. [Medline].
Badiozaman R, Tahereh P, Shideh D, Mohammadreza B, Ahmadreza A, Seyyedahmad T. Whole lung lavage of nine children with pulmonary alveolar proteinosis: experience in a tertiary lung center. Iran J Pediatr. 2013 Feb. 23(1):95-9. [Medline]. [Full Text].
Gonçalves BM, Teixeira VC, Bittencourt PF. Anesthesia for lung lavage in pediatric patient with pulmonary alveolar proteinosis. Rev Bras Anestesiol. 2012 Mar-Apr. 62(2):269-73. [Medline].
Wilson CA, Wilmshurst SL, Black AE. Anesthetic techniques to facilitate lung lavage for pulmonary alveolar proteinosis in children-new airway techniques and a review of the literature. Paediatr Anaesth. 2015 Jun. 25 (6):546-53. [Medline].
Reiter K, Schoen C, Griese M & Nicolai T. Whole-lung lavage in infants and children with pulmonary alveolar proteinosis. Pediatric Anesthesia. 2010. 20:1118-1123.
Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J. 2005 Jun. 25(6):1127. [Medline].
Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest. 1997 May. 111(5):1457-8. [Medline].
Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol. 2006 Apr. 41(4):367-70. [Medline].
Cho K, Nakata K, Ariga T, et al. Successful treatment of congenital pulmonary alveolar proteinosis with intravenous immunoglobulin G administration. Respirology. 2006 Jan. 11 Suppl:S74-7. [Medline].
Lee KN, Levin DL, Webb WR, et al. Pulmonary alveolar proteinosis: high-resolution CT, chest radiographic, and functional correlations. Chest. 1997 Apr. 111(4):989-95. [Medline].
Anton HC, Gray B. Pulmonary alveolar proteinosis presenting with pneumothorax. Clin Radiol. 1967 Oct. 18(4):428-31. [Medline].
Arora PL, Rogers RM, Mayock RL. Alveolar proteinosis. Experience with trypsin therapy. Am J Med. 1968 Jun. 44(6):889-99. [Medline].
Ballard PL, Nogee LM, Beers MF, et al. Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics. 1995 Dec. 96(6):1046-52. [Medline].
Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax. 2001 Aug. 56(8):664-5. [Medline].
Clague HW, Wallace AC, Morgan WK. Pulmonary interstitial fibrosis associated with alveolar proteinosis. Thorax. 1983 Nov. 38(11):865-6. [Medline].
Fisher M, Roggli V, Merten D, et al. Coexisting endogenous lipoid pneumonia, cholesterol granulomas, and pulmonary alveolar proteinosis in a pediatric population: a clinical, radiographic, and pathologic correlation. Pediatr Pathol. 1992 May-Jun. 12(3):365-83. [Medline].
Ganguli PC, Lynne-Davies P, Sproule BJ. Pulmonary alveolar proteinosis, bronchiectasis and secondary amyloidosis: a case report. Can Med Assoc J. 1972 Mar 4. 106(5):569 passim. [Medline].
Gough J. Silicosis and alveolar proteinosis. Br Med J. 1967 Mar 11. 1(540):629. [Medline].
Hamvas A. Surfactant protein B deficiency: insights into inherited disorders of lung cell metabolism. Curr Probl Pediatr. 1997 Oct. 27(9):325-45. [Medline].
Hildebrand FL Jr, Rosenow EC 3d, Habermann TM, Tazelaar HD. Pulmonary complications of leukemia. Chest. 1990 Nov. 98(5):1233-9. [Medline].
Hirakata Y, Kobayashi J, Sugama Y, Kitamura S. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J. 1995 May. 8(5):689-96. [Medline].
Honda Y, Kuroki Y, Shijubo N, et al. Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration. 1995. 62(2):64-9. [Medline].
Jansen HM, Zuurmond WW, Roos CM, et al. Whole-lung lavage under hyperbaric oxygen conditions for alveolar proteinosis with respiratory failure. Chest. 1987 Jun. 91(6):829-32. [Medline].
Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000 Aug. 162(2 Pt 1):658-62. [Medline].
Lin FC, Chen YC, Chang HI, Chang SC. Effect of body position on gas exchange in patients with idiopathic pulmonary alveolar proteinosis: no benefit of prone positioning. Chest. 2005 Mar. 127(3):1058-64. [Medline].
Martinez-Lopez MA, Gomez-Cerezo G, Villasante C, et al. Pulmonary alveolar proteinosis: prolonged spontaneous remission in two patients. Eur Respir J. 1991 Mar. 4(3):377-9. [Medline].
Nara M, Sano K, Ogawa H, et al. Serum antibody against granulocyte/macrophage colony-stimulating factor and KL-6 in idiopathic pulmonary alveolar proteinosis. Tohoku J Exp Med. 2006 Apr. 208(4):349-54. [Medline].
Nogee LM. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol. 2004. 66:601-23. [Medline].
Parto K, Kallajoki M, Aho H, Simell O. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. Hum Pathol. 1994 Apr. 25(4):400-7. [Medline].
Paschen C, Reiter K, Stanzel F, et al. Therapeutic lung lavages in children and adults. Respir Res. 2005. 6:138. [Medline].
Paschen C, Reiter K, Stanzel F, Teschler H and Griese M. Therapeutic lung lavages in children and adults. Respiratory Research. November 2005. 6:138. [Full Text].
Ranchod M, Bissell M. Pulmonary alveolar proteinosis and cytomegalovirus infection. Arch Pathol Lab Med. 1979 Mar. 103(3):139-42. [Medline].
Santamaria F, Brancaccio G, Parenti G et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child wiht lysinuric protein intolerance. Journal od Pediatrics. 2004. 145:268-72.
Seymour JF, Dunn AR, Vincent JM, et al. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med. 1996 Dec 19. 335(25):1924-5. [Medline].
Shah PL, Conway S, Scott SF, et al. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4-year period. Respiration. 2001. 68(2):160-4. [Medline].
Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax. 2000 Jan. 55(1):67-77. [Medline].
Stevens PA, Pettenazzo A, Brasch F, et al. Nonspecific interstitial pneumonia, alveolar proteinosis, and abnormal proprotein trafficking resulting from a spontaneous mutation in the surfactant protein C gene. Pediatr Res. 2005 Jan. 57(1):89-98. [Medline].
Summers JE. Pulmonary alveolar proteinosis. Review of the literature with follow-up studies and report of two new cases. Calif Med. 1966 Jun. 104(6):428-36. [Medline].
Sunderland WA, Campbell RA, Edwards MJ. Pulmonary alveolar proteinosis and pulmonary cryptococcosis in an adolescent boy. J Pediatr. 1972 Mar. 80(3):450-6. [Medline].
Tsai WC, Lewis D, Nasr SZ, Hirschl RB. Liquid ventilation in an infant with pulmonary alveolar proteinosis. Pediatr Pulmonol. 1998 Oct. 26(4):283-6. [Medline].
Berteloot L, Taam RA, Emond-Gonsard S, Mamou-Mani T, Lambot K, Grévent D, et al. Primary pulmonary alveolar proteinosis: computed tomography features at diagnosis. Pediatr Radiol. 2014 Jul. 44 (7):795-802. [Medline].